Načítá se...
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require a...
Uloženo v:
| Vydáno v: | Endocrinol Metab (Seoul) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Korean Endocrine Society
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090480/ https://ncbi.nlm.nih.gov/pubmed/33866776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2021.964 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|